Get the Stockscreener App
96.40
0.52%
-0.50
After Hours:
96.40
Mirum Pharmaceuticals Inc stock is traded at $96.40, with a volume of 463.12K.
It is down -0.52% in the last 24 hours and up +6.33% over the past month.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
See More
Previous Close:
$96.90
Open:
$97.3
24h Volume:
463.12K
Relative Volume:
0.55
Market Cap:
$5.82B
Revenue:
$521.31M
Net Income/Loss:
$-23.36M
P/E Ratio:
-201.63
EPS:
-0.4781
Net Cash Flow:
$54.87M
1W Performance:
-1.58%
1M Performance:
+6.33%
6M Performance:
+26.53%
1Y Performance:
+149.55%
1-Day Range:
$94.94
$97.37
1-Week Range:
$92.77
$99.23
52-Week Range:
$37.83
$109.28
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
96.40 | 5.85B | 521.31M | -23.36M | 54.87M | -0.4781 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-26 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-25 | Initiated | TD Cowen | Buy |
| Aug-11-25 | Resumed | Stifel | Buy |
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After Its Strong Multi‑Year Share Price Run? - Yahoo Finance
Mirum Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
ETF Watch: What are analysts price targets for Mirum Pharmaceuticals IncMarket Trend Report & Consistent Profit Alerts - baoquankhu1.vn
Aug Movers: Does Mirum Pharmaceuticals Inc stock benefit from AI growthMarket Activity Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Prediction: Buying This Biotech Stock Today Could Set You Up for Life - Yahoo Finance
Cantor Fitzgerald Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM) - The Globe and Mail
How Mirum Pharmaceuticals Inc. (MIRM) Affects Rotational Strategy Timing - Stock Traders Daily
Cantor Fitzgerald reiterates Mirum Pharmaceuticals stock rating By Investing.com - Investing.com Canada
Bluejay Therapeutics 2025 Financials: Mirum Pharmaceuticals Merger, Liquidity, and Key Financial Statements - Minichart
Mirum (MIRM) details Bluejay deal and $268.5M PIPE financing - Stock Titan
Primary Sclerosing Cholangitis Market is expected to Hit US$ - openPR.com
18,710 Shares in Mirum Pharmaceuticals, Inc. $MIRM Purchased by SG Americas Securities LLC - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates - MSN
Mirum (MIRM) Q1 2025 Earnings Call Transcript - AOL.com
MIRM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MIRM PE Ratio & Valuation, Is MIRM Overvalued - Intellectia AI
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) stock price, news, quote and history - Yahoo Finance UK
Why Is Mirum Pharmaceuticals (MIRM) Down 3.6% Since Last Earnings Report? - Eastern Progress
Mirum Pharmaceuticals, Inc. (MIRM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Mirum Pharmaceuticals (MIRM) Moves 5.1% Higher: Will This Strength Last? - qz.com
Mirum Pharmaceuticals (MIRM) Rises 5.1%: Can This Upward Momentum Continue? - Bitget
Mirum Pharma (MIRM) Earnings Call Transcript - The Globe and Mail
JPMorgan Chase & Co. Sells 380,067 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
(MIRM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
US Stocks Recap: Will Mirum Pharmaceuticals Inc stock hit new highs in YEARWeekly Profit Report & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Does Mirum Pharmaceuticals Inc stock benefit from AI growth2026 Earnings & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
A Look At Mirum Pharmaceuticals (MIRM) Valuation After Strong Long Term Share Performance - Yahoo Finance
Hennion & Walsh Asset Management Inc. Sells 17,560 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Tudor Investment Corp ET AL Makes New $2.03 Million Investment in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals Stock: Pipeline Progress and Rare Disease Focus for Long-Term Investor Value - AD HOC NEWS
Energy Moves: Will Mirum Pharmaceuticals Inc benefit from AI trendsWeekly Market Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Mirum Pharmaceuticals (MIRM) and NovoCure (NVCR) - The Globe and Mail
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $125.00 - MarketBeat
Vanguard disaggregates holdings; Mirum (MIRM) shows 0 shares owned - stocktitan.net
Mirum Pharmaceuticals Insiders Sell US$1.6m Of Stock, Possibly Signalling Caution - 富途牛牛
TD Cowen raises Mirum Pharmaceuticals stock price target to $125 - Investing.com
TD Cowen Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $125 - Moomoo
Citizens reiterates Mirum Pharmaceuticals stock rating on HDV data By Investing.com - Investing.com Canada
Citizens reiterates Mirum Pharmaceuticals stock rating on HDV data - Investing.com
Investor Mood: What are analysts price targets for Mirum Pharmaceuticals Inc2026 Institutional Moves & High Accuracy Trade Alerts - baoquankhu1.vn
Mirum completes enrollment & screening in liver disease studies - MSN
Citizens reiterates Mirum Pharmaceuticals stock rating ahead of data By Investing.com - Investing.com Canada
Citizens reiterates Mirum Pharmaceuticals stock rating ahead of data - Investing.com
Mirum Pharmaceuticals (NASDAQ:MIRM) Receives Buy Rating from HC Wainwright - marketbeat.com
Mirum Gains 35% in 3 Months: How Should You Play the Stock? - MSN
Is Mirum Pharmaceuticals (NASDAQ:MIRM) Stabilizing After Rating Updates? - Kalkine Media
Mirum Pharmaceuticals (MIRM) completes enrollment for phase 3 EXPAND study of LIVMARLI - MSN
Baird updates Mirum Pharmaceuticals (MIRM) valuation following beat-and-raise earnings results - MSN
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):